摘要
目的研究肺腺癌中血管内皮生长因子D及其受体表达水平与病灶氟代脱氧葡萄糖(FDG)摄取程度的关系,探讨FDG摄取程度是否可作为肺腺癌中预测靶向治疗疗效的一项指标。方法使用寡DNA基因芯片技术(Genespring 7.3)对6例肺腺癌病例行基因水平分析,并使用免疫组化方法对基因分析进一步证实。使用抗VEGF-D抗体对49例肺腺癌病理石蜡包埋切片行免疫组化染色。所有患者常规行PET检查,感兴趣区的定量分析采用标准摄取值(SUV)。使用独立样本t检验,χ2检验及F检验行统计学分析,使用Kaplan-Meier方法计算无病生存曲线。结果 VEGF-D表达在低FDG摄取组中远远高于高FDG摄取组(=0.0241)。免疫组化研究进一步证实:VEGF-D阴性组的FDG摄取程度明显高于阳性组(<0.001)。VEGF-D高表达组中发生淋巴结转移(<0.001)及复发(<0.001)的病例数均明显低于VEGF-D低表达组。VEGF-D高表达的患者其无病生存率明显高于低表达者。结论 VEGF-D表达与肺腺癌患者FDG摄取程度呈负相关,且可能作为肺腺癌患者淋巴结转移,组织学分型及复发的预测指标。
Objective We investigated the correlation between fluorodeoxyglucose (FDG) uptake on PET and the expression of vascular endothelial growth factor-D(VEGF-D) and VEGFRs in lung adenocarcinoma to find out whether PET can be a predictor for the target therapy. Methods The gene level study was achieved by oligo DNA microarray and analysed with Genespring 7.3 software. For further confirmation of protein level, VEGF-D immunohistochemical analysis was applied on consecutive paraffin-embedded sections obtained from 49 resected lung adenocarcinoma samples. All of the patients underwent both PET and surgery. Results The gene level expression of VEGF-D in low FDG uptake group was higher than that in high FDG uptake group ( P= 0.0241). FDG uptake was significantly higher ( P〈0.001), lymph node metastasis ( P〈0.001 both) and recurrence ( P〈0.001 and = 0.001 separately) occurred much often in VEGF-D negative group than in VEGF-D positive group. Patients with low VEGF-D had much better disease-free survival probabilities ( P 0.001). Conclusion VEGF-D expression is negatively correlated with FDG uptake ( P〈0.001), which might be an indictor for lymph node metastasis, histological subtypes and recurrence in lung adenocarcinoma.
出处
《解剖科学进展》
CAS
2010年第3期230-234,239,共6页
Progress of Anatomical Sciences
关键词
肺腺癌
氟代脱氧葡萄糖
血管内皮生长因子D
血管内皮生长因子受体
lung adenocarcinoma
fluorodeoxyglucose
vascular endothelial growth factors (VEGFs)
vascular endothelial growth factor receptors (VEGFRs)